Proteostasis Triad Pulses is a novel therapeutic strategy that employs staggered, pulsed interventions across all three pillars of the cellular proteostasis network: integrated stress response (ISR) modulation, autophagy induction, and molecular chaperone upregulation. This approach addresses the fundamental bottleneck in neurodegenerative disease: the simultaneous failure of multiple interconnected proteostasis mechanisms that leads to toxic protein aggregation. [1] [2]
The strategy uses temporal staggering to prevent adaptive downregulation—a critical limitation of continuous proteostasis activation. By sequencing interventions across the ISR, autophagy-lysosome, and ubiquitin-proteasome systems, this therapy aims to restore the cell's capacity to clear pathological proteins including amyloid-beta, alpha-synuclein, tau, and TDP-43. [3] [4]
| Attribute | Value |
|---|---|
| Therapy Name | Proteostasis Triad Pulses |
| Category | Combination logic |
| Target Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, FTD |
| Total Score | 78/100 |
| AD Score | 8/10 |
| PD Score | 8/10 |
| ALS Score | 8/10 |
| FTD Score | 8/10 |
| Aging Score | 8/10 |
Neurodegenerative diseases are characterized by the accumulation of misfolded and aggregated proteins in the brain. In Alzheimer's disease, amyloid-beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau accumulate. Parkinson's disease features Lewy bodies rich in alpha-synuclein. ALS and frontotemporal dementia involve TDP-43 aggregates. A unifying feature of these conditions is the failure of the proteostasis network—the cellular system responsible for protein folding, quality control, and degradation. [5] [6]
The proteostasis network consists of three major arms:
Integrated Stress Response (ISR): A signaling network that detects proteotoxic stress and either restores homeostasis or executes apoptosis. Chronic ISR activation leads to translational repression that impairs synaptic function and neuronal survival. [7]
Autophagy-Lysosome Pathway (ALP): The primary degradation system for aggregates, damaged organelles, and long-lived proteins. Autophagy declines with age and is impaired in neurodegenerative diseases. [8]
Molecular Chaperones: Heat shock proteins (HSPs) that assist protein folding and prevent aggregation. Chaperone expression decreases with age, reducing the cell's ability to prevent aggregate formation. [9]
Critically, these three systems are not independent—they are interconnected through transcriptional programs (e.g., TFEB regulates both autophagy and lysosomal genes), post-translational modifications, and shared substrate loading. Single-arm interventions (e.g., autophagy induction alone) often fail because the other arms remain bottleneck. [10]
The Proteostasis Triad Pulses approach addresses this limitation by sequentially activating all three arms:
Phase 1: ISR Modulation (Weeks 1-4)
Phase 2: Autophagy Induction (Weeks 5-12)
Phase 3: Chaperone Induction (Weeks 13-20)
Cycle Repetition: The tri-phasic protocol is repeated with decreasing intensity for maintenance (every 6-12 months), preventing aggregate re-accumulation while minimizing long-term drug exposure.
Continuous proteostasis activation leads to several problems:
Pulsed dosing allows:
| Biomarker | Pathway | Measurement |
|---|---|---|
| p-eIF2α/eIF2α ratio | ISR | CSF or blood |
| LC3-II/LC3-I ratio | Autophagy | Peripheral blood mononuclear cells |
| TFEB nuclear translocation | Autophagy | Skin fibroblast assay |
| HSP70 levels | Chaperones | CSF or blood |
| Neurofilament light chain (NfL) | Neurodegeneration | CSF or blood |
| Total tau/phospho-tau | AD pathology | CSF |
Year 1: Lead Optimization
Year 2: Disease Model Testing
Year 3: IND-Enabling Studies
Phase 1 (Year 4)
Phase 2a (Year 5)
Phase 2b (Year 6)
Phase 3 (Year 7)
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Compound toxicity | Medium | High | Extensive PK/PD screening; backup compounds |
| Insufficient CNS penetration | High | High | Focus on brain-penetrant analogs; intranasal delivery |
| Lack of biomarker correlation | Medium | Medium | Multiple biomarker approaches; adaptive design |
| Competitive programs | High | Medium | Accelerate timeline; differentiate via triple combination |
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8/10 | Pulsed/staggered proteostasis approach is novel; sequential modulation not yet in clinic |
| Mechanistic Rationale | 9/10 | Strong scientific basis for targeting all three proteostasis pillars; addresses network collapse |
| Addresses Root Cause | 8/10 | Targets proteostasis failure, a fundamental mechanism in neurodegeneration |
| Delivery Feasibility | 6/10 | Multiple interventions required; pulsed delivery may help but BBB remains challenge |
| Safety Plausibility | 7/10 | Each component has safety data; combination requires careful optimization |
| Combinability | 9/10 | Highly compatible with other approaches; could enhance amyloid/tau/alpha-syn clearance |
| Biomarker Availability | 7/10 | Proteostasis markers exist but need validation for this specific approach |
| De-risking Path | 6/10 | Novel mechanism requires extensive preclinical validation |
| Multi-disease Potential | 9/10 | Applies to AD, PD, ALS, FTD, Huntington's - all protein aggregation diseases |
| Patient Impact | 8/10 | Could significantly slow disease progression if effective |
Total: 77/100
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7/10/10 | Proteostasis triad modulation is established; pulse therapy is innovative |
| Mechanistic Rationale | 8/10/10 | Addresses all three branches of proteostasis: UPS, autophagy, ERAD |
| Addresses Root Cause | 8/10/10 | Comprehensive proteostasis restoration - addresses protein aggregation directly |
| Delivery Feasibility | 6/10/10 | Multiple drug delivery; pulse timing adds complexity |
| Safety Plausibility | 6/10/10 | Pulsed therapy may reduce chronic exposure; safety monitoring needed |
| Combinability | 7/10/10 | Excellent foundation; built-in combination of mechanisms |
| Biomarker Availability | 6/10/10 | Proteostasis biomarkers available; pulse optimization challenging |
| De-risking Path | 6/10/10 | Requires validation of pulse timing in clinical trials |
| Multi-disease Potential | 7/10/10 | Relevant for AD, PD, ALS, Huntington disease |
| Patient Impact | 8/10/10 | Could comprehensively address protein aggregation |
| Total | 69/100 |
Sala et al. Proteostasis collapse in aging and neurodegeneration (2020). 2020. ↩︎
Klaips et al. Pathways of cellular proteostasis in aging and disease (2018). 2018. ↩︎
Hippert et al. Integrated stress response in Alzheimer's disease (2022). 2022. ↩︎
Menzies et al. Autophagy and neurodegeneration (2017). 2017. ↩︎
Balch et al. Taking the measure of the proteostasis network (2008). 2008. ↩︎
Wolfe et al. Targeting proteostasis in neurodegenerative disease (2023). 2023. ↩︎
Costa-Mattioli & Walter, The integrated stress response (2020). 2020. ↩︎
Mizushima & Komatsu, Autophagy: renovation of cells and tissues (2011). 2011. ↩︎
Hartl & Hayer-Hartl, Molecular chaperones in protein folding (2009). 2009. ↩︎
Song et al. Systems analysis of proteostasis reveals a coordinated strategy (2023). 2023. ↩︎
Grosely et al. ISRIB reverses stress-induced translation repression (2022). 2022. ↩︎
Sardiello et al. TFEB regulates cellularClearance (2023). 2023. ↩︎
Neckers & Tatu, HSP90 inhibitors as anticancer agents (2022). 2022. ↩︎
Liu & Klionsky, The principles of pulsed autophagy (2021). 2021. ↩︎
Cai et al. ISRIB improves cognition in AD mice (2022). 2022. ↩︎
Moon et al. ISRIB reduces tau pathology (2023). 2023. ↩︎
Yoon et al. eIF2α phosphorylation regulates memory (2022). 2022. ↩︎
Spilman et al. Rapamycin improves cognition in AD mice (2010). 2010. ↩︎
Decressac et al. TFEB reduces alpha-synuclein (2019). 2019. ↩︎
Zhang et al. Trehalose in ALS models (2021). 2021. ↩︎
Cao et al. HSP70 reduces tau pathology (2021). 2021. ↩︎
Waza et al. HSP90 inhibitors in polyglutamine disease (2005). 2005. ↩︎
Kieran et al. HSP90 inhibition in SOD1 mice (2004). 2004. ↩︎
Bauer et al. Synergistic proteostasis therapy (2020). 2020. ↩︎
Pfleger et al. Computational modeling of triple proteostasis intervention (2023). 2023. ↩︎